A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Arcus Biosciences, Inc.
Ohio State University Comprehensive Cancer Center
Taiho Pharmaceutical Co., Ltd.
Merck Sharp & Dohme LLC
Fox Chase Cancer Center
TG Therapeutics, Inc.
Wake Forest University Health Sciences
Mayo Clinic
Roswell Park Cancer Institute
Valerio Therapeutics
Roswell Park Cancer Institute
Stanford University
National Institutes of Health Clinical Center (CC)
Teikyo University